Prognostic Utility of the Ki-67 Labeling Index in Follicular Thyroid Tumors: a 20-Year Experience from a Tertiary Thyroid Center

[1]  M. Papotti,et al.  Overview of the 2022 WHO Classification of Thyroid Neoplasms , 2022, Endocrine Pathology.

[2]  C. Larsson,et al.  Nuclear-specific accumulation of telomerase reverse transcriptase (TERT) mRNA in TERT promoter mutated follicular thyroid tumours visualised by in situ hybridisation: a possible clinical screening tool? , 2021, Journal of Clinical Pathology.

[3]  J. Zedenius,et al.  The Clinical Significance of Lymph Node Ratio and Ki-67 Expression in Papillary Thyroid Cancer , 2021, World Journal of Surgery.

[4]  C. Juhlin,et al.  Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry , 2021, Endocrine Pathology.

[5]  T. Giordano,et al.  What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics , 2021, Endocrine Pathology.

[6]  L. Erickson,et al.  Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice , 2020, Endocrine Pathology.

[7]  C. Larsson,et al.  Spatial distribution patterns of clinically relevant TERT promoter mutations in follicular thyroid tumors of uncertain malignant potential (FT-UMPs): advantages of the digital droplet PCR (ddPCR) technique. , 2020, The Journal of molecular diagnostics : JMD.

[8]  R. Korah,et al.  Transcription Factor Profiling Identifies Spatially Heterogenous Mediators of Follicular Thyroid Cancer Invasion , 2020, Endocrine Pathology.

[9]  C. Juhlin.  A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert! , 2020, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.

[10]  C. Larsson,et al.  Clinical Routine TERT Promoter Mutational Screening of Follicular Thyroid Tumors of Uncertain Malignant Potential (FT-UMPs): A Useful Predictor of Metastatic Disease , 2019, Cancers.

[11]  T. Nagayasu,et al.  TERT mRNA expression as a novel prognostic marker in papillary thyroid carcinomas. , 2019, Thyroid : official journal of the American Thyroid Association.

[12]  Baocun Sun,et al.  Expression of epithelial‐mesenchymal transition regulators TWIST, SLUG and SNAIL in follicular thyroid tumours may relate to widely invasive, poorly differentiated and distant metastasis , 2019, Histopathology.

[13]  F. Borson‐Chazot,et al.  TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma. , 2019, European journal of cancer.

[14]  C. Larsson,et al.  Comprehensive Genetic Analysis of Follicular Thyroid Carcinoma Predicts Prognosis Independent of Histology , 2018, The Journal of clinical endocrinology and metabolism.

[15]  C. Larsson,et al.  TERT aberrancies: a screening tool for malignancy in follicular thyroid tumours. , 2018, Endocrine-related cancer.

[16]  C. Larsson,et al.  High Ki-67 index in fine needle aspiration cytology of follicular thyroid tumors is associated with increased risk of carcinoma , 2018, Endocrine.

[17]  S. Asa,et al.  Immunohistochemical Biomarkers in Thyroid Pathology , 2018, Endocrine Pathology.

[18]  L. Dizdar,et al.  Survivin and XIAP – two potential biological targets in follicular thyroid carcinoma , 2017, Scientific Reports.

[19]  R. Lloyd,et al.  WHO classification of tumours of endocrine organs , 2017 .

[20]  M. Hirokawa,et al.  Prognostic impact of Ki-67 labeling index in minimally invasive follicular thyroid carcinoma. , 2016, Endocrine journal.

[21]  A. Samir,et al.  Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology. , 2015, AJR. American journal of roentgenology.

[22]  C. Haglund,et al.  Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas. , 2015, Human pathology.

[23]  Yasuhiro Ito,et al.  Prognostic classification of thyroid follicular cell tumors using Ki-67 labeling index: risk stratification of thyroid follicular cell carcinomas. , 2015, Endocrine journal.

[24]  C. Larsson,et al.  The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas , 2014, Oncogene.

[25]  S. Ito,et al.  Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. , 2014, Endocrine-related cancer.

[26]  M. Copin,et al.  Poorly differentiated thyroid carcinomas: application of the Turin proposal provides prognostic results similar to those from the assessment of high‐grade features , 2014, Histopathology.

[27]  Somak Roy,et al.  Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. , 2013, The Journal of clinical endocrinology and metabolism.

[28]  T. Chan,et al.  Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. , 2013, The Journal of clinical endocrinology and metabolism.

[29]  D. Duick,et al.  The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. , 2012, Thyroid : official journal of the American Thyroid Association.

[30]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[31]  C. Larsson,et al.  Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy. , 2009, International journal of oncology.

[32]  A. Scarpa,et al.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system , 2006, Virchows Archiv : an international journal of pathology.

[33]  J. Shah,et al.  Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis , 2006, Cancer.

[34]  B. Weinhold.  Epigenetics: The Science of Change , 2006, Virchows Archiv.

[35]  O. Topolcan,et al.  Proliferative markers in diagnosis of thyroid tumors: a comparative study of MIB-1 and topoisomerase II-a immunostaining. , 2005, Anticancer research.

[36]  C. Larsson,et al.  MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma. , 2003, Thyroid : official journal of the American Thyroid Association.

[37]  C. Mittermayer,et al.  MIB-1 immunohistometry of follicular adenoma and follicular carcinoma of the thyroid gland. , 2000, Analytical and quantitative cytology and histology.

[38]  D. Zelterman,et al.  Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. , 1999, The American journal of surgical pathology.

[39]  P. De Giuli,et al.  Galectin-3 is a presurgical marker of human thyroid carcinoma. , 1998, Cancer research.

[40]  P. Wollan,et al.  Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[41]  R. Lotan,et al.  Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. , 1995, The American journal of pathology.

[42]  T. Oyama,et al.  Growth activity in hyperplastic and neoplastic human thyroid determined by an immunohistochemical staining procedure using monoclonal antibody MIB-1. , 1995, Human pathology.

[43]  P. Wollan,et al.  Immunohistochemical analysis of the cell cycle-associated antigens Ki-67 and retinoblastoma protein in parathyroid carcinomas and adenomas , 1995, Endocrine pathology.

[44]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.